Reported / Citable
Background
Nine providers of skin-substitute products sued HHS officials over Medicare claim denials and recoupment efforts involving products derived from donated human amniotic tissue. They alleged that CMS had adopted an unlawful “Clawback Policy” requiring peer-reviewed scientific literature establishing the effectiveness of a particular product; absent that evidence, the products were treated as experimental or investigational and not covered.
The providers sought class certification, declaratory relief that the policy was unlawful and that the products were reasonable and necessary under Medicare, and an injunction requiring reimbursement. Six plaintiffs had not completed Medicare’s administrative appeals process. Three had exhausted or otherwise reached a stage permitting judicial review, but they were located outside the Northern District of Texas.
The Court’s Holding
The court granted the government’s Rule 12(b)(1) motion and dismissed the action. Claims arising under the Medicare Act must proceed through the statute’s administrative-review scheme before judicial review under 42 U.S.C. § 405(g). The six unexhausted plaintiffs sought, in substance, payment of Medicare claims and a determination that recoupments and denials were unlawful; those claims were not collateral to the benefits determinations and did not qualify for a futility-based waiver of exhaustion.
The court then dismissed the remaining plaintiffs for improper venue. Once Texas-based plaintiff Chris McGee was dismissed, no remaining plaintiff supported venue in the Northern District of Texas. The court declined to transfer because the remaining claims involved different products and procedural paths. It also denied leave to amend, finding the record established that plaintiffs could not establish jurisdiction in that court. All other pending motions were denied as moot.
Key Takeaways
- Medicare providers generally must exhaust the statutory administrative process before seeking federal-court review of coverage, denial, or recoupment disputes.
- Characterizing a reimbursement dispute as a challenge to an agency policy does not make it collateral when the requested relief requires deciding entitlement to Medicare payment.
- Venue for Medicare judicial review depends on the plaintiff’s location or principal place of business, and the court may dismiss rather than transfer where plaintiffs’ claims materially differ.
Why It Matters
The decision reinforces the restrictive jurisdictional path for provider challenges to Medicare payment decisions. Providers contesting skin-substitute denials or recoupments must ordinarily complete the administrative process before asking a federal court to address the merits.
It also illustrates the need to assess venue separately for each provider, particularly where multiple providers bring claims involving different products, claims, and administrative histories.